GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 05:23:00 2025-12-12 am EST			5-day change	1st Jan Change
1,826.50 ^GBX	+0.30%		+1.52%	+36.09%

05:06am	GSK Gets US FDA Approval for Gepotidacin to Treat Uncomplicated Urogenital Gonorrhoea	MT
04:23am	GSK's Arexvy on track for wider age range approval in Europe	AN

Transcript : GSK plc, Q4 2024 Earnings Call, Feb 05, 2025

Published on 02/05/2025 at 05:45 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, everyone. Welcome to today's call and webcast. The presentation was sent to our distribution list by e-mail, and you can also find it on

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about GSK plc

05:06am	GSK Gets US FDA Approval for Gepotidacin to Treat Uncomplicated Urogenital Gonorrhoea	MT
04:23am	GSK's Arexvy on track for wider age range approval in Europe	AN
02:44am	FTSE 100 to rise, UK GDP down, trade deficit spikes	AN
02:35am	GSK's RSV Vaccine Bags European Recommendation for Expanded Use	MT
02:28am	GSK gets EU regulator backing for expanded use of RSV vaccine	RE
02:15am	GSK announces positive CHMP opinion on Arexvy for all adults aged 18 and above	RE
03:06am	UK Stocks-Factors to watch on December 12	RE
11:22pm	GSK Wins US FDA Approval for Uncomplicated Urogenital Gonorrhoea Antibiotic	MT
Dec. 11	GSK Says FDA Approved Oral Treatment for Gonorrhea	DJ
Dec. 11	GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication	CI
Dec. 11	FDA approves BluJepa for uncomplicated urogenital gonorrhea in some patients	RE
Dec. 11	US FDA expands use of GSK's Blujepa as treatment for gonorrhea	RE
Dec. 11	Fda: approves blujepa for uncomplicated urogenital gonorrhea in some adult & pediatric patients 12 years of age & older - website	RE
Dec. 11	Outgoing GSK CEO Emma Walmsley declares US best place to invest	AN
Dec. 10	Sector Update: Health Care Stocks Rise Premarket Wednesday	MT
Dec. 10	GSK Bolsters Oncology Pipeline with New US FDA Designation, Oxford BioTherapeutics Partnership	MT
Dec. 10	GSK Says Risvutatug Rezetecan Gets FDA Orphan Drug Designation For Small-Cell Lung Cancer Treatment	MT
Dec. 10	GSK Forms Collaboration With Oxford BioTherapeutics to Discover Antibody-Based Cancer Treatments	MT
Dec. 10	GSK small-cell lung cancer drug gets support from US FDA	AN
Dec. 10	GSK, Oxford BioTherapeutics Partner to Discover Cancer Drug Targets	MT
Dec. 10	GSK Wins US FDA's Orphan Drug Designation for Small-cell Lung Cancer Treatment	MT
Dec. 10	GSK announces GSK'227 US FDA Orphan Drug Designation in SCLC	RE
Dec. 10	Oxford BioTherapeutics Enters into A Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer	CI
Dec. 10	GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer	CI
Dec. 09	GSK : JP Morgan keeps a Sell rating	ZD